News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,206 Results
Type
Article (14258)
Company Profile (281)
Press Release (253667)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79532)
Career Advice (152)
Deals (13231)
Drug Delivery (35)
Drug Development (50475)
Employer Resources (31)
FDA (5727)
Job Trends (5146)
News (144457)
Policy (10038)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21673)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5755)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4572)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (155)
Cancer (1485)
Cardiovascular disease (117)
Career advice (133)
Career pathing (2)
CAR-T (118)
Cell therapy (332)
Cervical cancer (8)
Clinical research (41105)
Collaboration (542)
Compensation (263)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1532)
Denatured (11)
Depression (31)
Diabetes (140)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29858)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48624)
Executive appointments (464)
FDA (6435)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1083)
Grass and pollen (2)
Guidances (27)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (211)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2600)
Medtech (2601)
Mergers & acquisitions (6288)
Metabolic disorders (392)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1260)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (79)
Peanut (35)
People (25654)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14518)
Phase II (19113)
Phase III (12094)
Pipeline (818)
Policy (46)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8654)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (214)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (77)
Last 7 days (543)
Last 30 days (1496)
Last 365 days (19526)
2025 (6352)
2024 (20556)
2023 (22421)
2022 (26831)
2021 (27809)
2020 (23358)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11841)
2015 (14350)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17316)
Australia (2935)
California (3885)
Canada (1144)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37258)
Florida (468)
Georgia (117)
Idaho (16)
Illinois (233)
India (10)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (478)
Massachusetts (3094)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (971)
New Mexico (12)
New York (1050)
North Carolina (556)
North Dakota (5)
Northern California (1715)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1496)
Tennessee (25)
Texas (450)
United States (13329)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,206 Results for "tenaya therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies
The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The company is continuing to test its hypertrophic cardiomyopathy gene therapy.
April 1, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Tenaya Therapeutics Announces Proposed Public Offering
March 4, 2025
·
4 min read
Press Releases
Tenaya Therapeutics Announces Pricing of Public Offering
March 4, 2025
·
5 min read
Press Releases
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
March 3, 2025
·
1 min read
Cardiovascular disease
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data
Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair analysts.
December 18, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
·
12 min read
Press Releases
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
March 24, 2025
·
9 min read
Press Releases
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
March 19, 2025
·
3 min read
Press Releases
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
January 14, 2025
·
10 min read
Press Releases
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
February 3, 2025
·
8 min read
1 of 26,821
Next
